Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Mar;6(2):193-215.
doi: 10.2217/17410541.6.2.193.

Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses

Ilia L Ferrusi  1 , Deborah A Marshall, Nathalie A Kulin, Natasha B Leighl, Kathryn A Phillips
Affiliations

Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses

Ilia L Ferrusi et al. Per Med. 2009 Mar.

Abstract

Trastuzumab is a targeted therapy for human EGF receptor-2 (HER2)-positive breast cancer. The effectiveness and cost-effectiveness of trastuzumab hinges not only on its clinical efficacy in responding patients, but on the ability to accurately identify appropriate therapeutic candidates. We sought to systematically review the cost-effectiveness of trastuzumab with a focus on the impact of the test(s) used for HER2 diagnosis. Our review included 17 economic evaluations or health technology assessments of trastuzumab therapy or HER2 testing. Trastuzumab was considered cost-effective in all early-stage disease studies, while one author concluded that trastuzumab was not cost-effective for metastatic disease. Only two papers considered the joint effects of test accuracy and sequencing with trastuzumab therapy. These demonstrated that trastuzumab cost-effectiveness is sensitive to HER2-test properties.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Quorum diagram depicting the flow of studies through the review process
HER2: Human EGF-2 receptor.
See this image and copyright information in PMC

References

Bibliography

    1. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 2006;354:809–820. - PubMed
    1. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002;62:209–243. - PubMed
    1. De Laurentiis M, Cancello G, Zinno L, et al. Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. Ann. Oncol. 2005;16 Suppl. 4:IV7–IV13. - PubMed

    1. Dendukuri N, Khetani K, McIsaac M, Brophy J. Testing for HER2-positive breast cancer: a systematic review and cost– effectiveness analysis. Can. Med. Assoc. J. 2007;176:1429–1434. ▪ Presents one methodology for the synthesis of human EGF receptor-2 (HER2) test accuracy data and the integration of this information into cost–effectiveness analysis

    1. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007;25:118–145. - PubMed

Websites

    1. Doherty D. Roche sales fall 4% on lower demand for Tamiflu. 2008. www.bloomberg.com/apps/news?pid=20670001&refer=home&sid=aIW.jE9ReeJU.
    1. US Federal Reserve: Foreign exchange rates (annual) 1999. www.federalreserve.gov/releases/g5a/19990104/
    1. US Federal Reserve: Foreign exchange rates (annual) 2007. www.federalreserve.gov/releases/g5a/20070103/
    1. US Federal Reserve: Foreign exchange rates (annual) 2008. www.federalreserve.gov/releases/g5a/20030106/
    1. US Federal Reserve: Foreign exchange rates (annual) 2008. www.federalreserve.gov/releases/g5a/current/